SCHEMBL990608

SCHEMBL990608

Cc1cnc(Cl)cc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29739219 1.00
SCHEMBL1644729 0.81
SCHEMBL30669490 0.81
SCHEMBL828274 0.79
SCHEMBL16310618 0.79
SCHEMBL19229099 0.75
SCHEMBL19434149 0.75
SCHEMBL4829874 0.75
SCHEMBL2596935 0.75
SCHEMBL21737261 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104703473-B Composition comprising desinsection terpene blend and fungicide 拜耳农作物科学股份公司 2017-12-29 CN claimed
US-12575314-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2026-03-10 US disclosed
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-03-10 US disclosed
US-20260014260-A1 MDM2 DEGRADER NEWAVE PHARMACEUTICAL INC (US) 2026-01-15 US disclosed
EP-4612153-A1 PREPARATION OF PYRAZOLOPYRIDINE AND TRIAZOLOPYRIDINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2025-09-10 EP disclosed
WO-2025111251-A1 COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 EXELIXIS, INC. (US) 2025-05-30 WO disclosed
WO-2025090480-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-05-01 WO disclosed
US-20250073340-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF NEWAVE PHARMACEUTICAL INC. 2025-03-06 US disclosed
US-20250017031-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2025-01-09 US disclosed
US-20240341165-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-10-10 US disclosed
EP-1904457-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY Rigel Pharmaceuticals, Inc. (US) 2008-04-02 EP disclosed
EP-1737862-A4 IMIDAZOPYRIDINE COMPOUND EISAI R&D MAN CO LTD (JP) 2007-11-28 EP disclosed
EP-1745037-A1 INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS Novartis AG (CH) 2007-01-24 EP disclosed
EP-1737862-A1 IMIDAZOPYRIDINE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-01-03 EP disclosed
US-20060293311-A1 e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease RIGEL PHARMACEUTICALS, INC. 2006-12-28 US disclosed
WO-2006133426-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2006-12-14 WO disclosed
US-20060167041-A1 such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-07-27 US disclosed
US-20050272764-A1 Imidazopyridine compound EISAI CO., LTD. 2005-12-08 US disclosed
WO-2005103049-A1 IMIDAZOPYRIDINE COMPOUND EISAI R & D MANAGEMENT CO., LTD. (JP) 2005-11-03 WO disclosed
WO-2005068455-A1 INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS NOVARTIS AG (CH) 2005-07-28 WO disclosed